These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8148667)

  • 1. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
    Reginster JY
    Bone Miner; 1993 Dec; 23(3):223-32. PubMed ID: 8148667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipriflavone: an important bone-building isoflavone.
    Head KA
    Altern Med Rev; 1999 Feb; 4(1):10-22. PubMed ID: 9988779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ipriflavone].
    Kitatani K; Morii H
    Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
    Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
    Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
    Reginster JY
    Bone; 1992; 13(5):351-4. PubMed ID: 1419375
    [No Abstract]   [Full Text] [Related]  

  • 6. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium ranelate in osteoporosis.
    Reginster JY
    Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miscellaneous and experimental agents.
    Reginster JY
    Am J Med Sci; 1997 Jan; 313(1):33-40. PubMed ID: 9001164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
    Agnusdei D; Adami S; Cervetti R; Crepaldi G; Di Munno O; Fantasia L; Isaia GC; Letizia G; Ortolani S; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S43-8. PubMed ID: 1422320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
    Kovács AB
    Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term treatment of Paget's disease of bone with ipriflavone.
    Agnusdei D; Camporeale A; Gonnelli S; Gennari C; Baroni MC; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S35-42. PubMed ID: 1422319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs.
    Brandi ML
    Am J Med; 1993 Nov; 95(5A):69S-74S. PubMed ID: 8256800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipriflavone inhibits bone resorption in intact and ovariectomized rats.
    Cecchini MG; Fleisch H; Mühibauer RC
    Calcif Tissue Int; 1997; 61 Suppl 1():S9-11. PubMed ID: 9263609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
    Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
    Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
    Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.